Metastatic breast cancer global perspectives by clinical experts

Practice changes and horizon openings from ESMO 2019 and beyond: immunotherapy, PARP inhibitors, AKT drugs, Survival data with CDK4/6 inhibitors.

Faculty Co-Chair

Nadia Harbeck

Nadia Harbeck MD, PhD

Ludwig-Maximilians-University of Munich LMU – Breast Center, Germany

Faculty Co-Chair

Mohammad Jahanzeb, MD, FACP

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, USA

Look Inside This Report

Download a sample of the highligts report and start discovering the insights.

Key Topics

  • The extent to which scientific experts have consensus on the best ways of treating triple-negative breast cancer: immunotherapy, PARP inhibitors, AKT drugs
  • Immunotherapy – expert recommendations about the benefits and the place of this treatment option
  • Cytotoxic chemotherapy – expert opinions around the future use of this type of therapy
  • The latest CDK4/6 inhibitors survival data: experts discuss to what extent CDK4/6 inhibitors are alike and to what extent these data will change the treatment algorithm
  • How to appropriately maximize the benefits of targeted therapies in breast cancer on the basis of  reported data that are practice-changing, as well as hypothesis generating for future trials
  • Expert opinions on how new reported data in HER2+ breast cancer will change its treatment

Expert Faculty

Lisa A. Carey, MD
University of North Carolina at Chapel Hill, United States

Javier Cortes, MD
Vall d´Hebron Institute of Oncology (VHIO), Spain

Alessandra Gennari, MD, PhD
University of Eastern Piedmont, Italy

Joyce O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Per Lønning, MD, PhD
University of Bergen, Norway

Peter Schmid, MD, PhD
Barts Cancer Institute, United Kingdom

Explore Available and Upcoming Insight Reports

View Reports